Analyses of treatment outcomes by DNA repair genotypes
| Polymorphism . | Total no. . | CR . | RD . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. . | OR . | CI . | No. . | OR . | CI . | No. of deaths . | HR . | CI . | ||
| APE1 Asp148Glu | ||||||||||
| GG | 51 | 21 | 1.00 | 14 | 1.00 | NA | 46 | 1.00 | NA | |
| GT | 68 | 27 | 0.93 | 0.41-2.13 | 29 | 2.08 | 0.90-4.98 | 63 | 0.97 | 0.66-1.43 |
| TT | 53 | 22 | 1.13 | 0.46-2.79 | 17 | 0.90 | 0.34-2.33 | 50 | 0.96 | 0.64-1.45 |
| GT or TT | 121 | 49 | 1.00 | 0.48-2.14 | 46 | 1.49 | 0.70-3.30 | 113 | 0.96 | 0.68-1.37 |
| Total | 172 | 70 | NA | NA | 60 | NA | NA | 159 | NA | NA |
| XRCC1 Arg399Gln | ||||||||||
| GG* | 88 | 40 | 1.00 | 31 | 1.00 | NA | 81 | 1.00 | NA | |
| GA | 83 | 38 | 0.91 | 0.47-1.77 | 24 | 0.87 | 0.44-1.73 | 78 | 1.12 | 0.82-1.54 |
| AA | 16 | 4 | 0.27 | 0.05-0.99 | 5 | 0.85 | 0.24-2.75 | 15 | 1.54 | 0.86-2.74 |
| GA or AA | 99 | 42 | 0.76 | 0.40-1.44 | 29 | 0.87 | 0.45-1.67 | 93 | 1.17 | 0.86-1.59 |
| Total | 187 | 82 | NA | NA | 60 | NA | NA | 174 | NA | NA |
| XRCC3 Thr241Met | ||||||||||
| CC* | 89 | 35 | 1.00 | NA | 35 | 1.00 | NA | 85 | 1.00 | NA |
| CT | 74 | 30 | 0.84 | 0.41-1.70 | 22 | 0.68 | 0.33-1.36 | 66 | 0.90 | 0.65-1.25 |
| TT | 15 | 8 | 1.90 | 0.54-6.95 | 4 | 0.67 | 0.16-2.33 | 13 | 0.83 | 0.46-1.50 |
| CT or TT | 89 | 38 | 0.97 | 0.50-1.89 | 26 | 0.68 | 0.35-1.32 | 79 | 0.89 | 0.65-1.21 |
| Total | 178 | 73 | NA | NA | 61 | NA | NA | 164 | NA | NA |
| ERCC1 IVS5+34C>A | ||||||||||
| CC* | 143 | 60 | 1.00 | NA | 48 | 1.00 | NA | 131 | 1.00 | NA |
| CA | 45 | 22 | 1.57 | 0.75-3.35 | 12 | 0.59 | 0.26-1.30 | 43 | 1.08 | 0.75-1.56 |
| AA | 4 | 1 | 0.50 | 0.02-4.27 | 2 | 1.51 | 0.16-14.28 | 4 | 2.04 | 0.74-5.62 |
| CA or AA | 49 | 23 | 1.43 | 0.6-2.97 | 14 | 0.65 | 0.29-1.38 | 47 | 1.13 | 0.79-1.60 |
| Total | 192 | 83 | NA | NA | 62 | NA | NA | 178 | NA | NA |
| XPD Lys751Gln | ||||||||||
| AA | 86 | 31 | 1.00 | 37 | 1.00 | NA | 80 | 1.00 | NA | |
| AC | 84 | 43 | 1.97 | 0.91-4.37 | 21 | 0.43 | 0.18-0.96 | 77 | 0.95 | 0.66-1.36 |
| CC | 27 | 11 | 1.57 | 0.44-5.53 | 6 | 0.24 | 0.05-0.97 | 25 | 1.04 | 0.58-1.87 |
| AC or CC | 111 | 54 | 1.89 | 0.90-4.01 | 27 | 0.39 | 0.17-0.83 | 102 | 0.97 | 0.68-1.36 |
| Total | 197 | 85 | NA | NA | 64 | NA | NA | 182 | NA | NA |
| XPD Asp312Asn | ||||||||||
| GG | 95 | 42 | 1.00 | 39 | 1.00 | NA | 88 | 1.00 | NA | |
| GA | 79 | 34 | 1.50 | 0.70-3.26 | 19 | 0.44 | 0.19-1.00 | 73 | 1.00 | 0.70-1.44 |
| AA | 19 | 6 | 0.31 | 0.05-1.43 | 6 | 1.04 | 0.24-4.21 | 18 | 2.31 | 1.19-4.49 |
| GA or AA | 98 | 40 | 1.20 | 0.58-2.51 | 25 | 0.52 | 0.24-1.11 | 91 | 1.11 | 0.79-1.57 |
| Total | 193 | 82 | NA | NA | 64 | NA | NA | 179 | NA | NA |
| Polymorphism . | Total no. . | CR . | RD . | OS . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. . | OR . | CI . | No. . | OR . | CI . | No. of deaths . | HR . | CI . | ||
| APE1 Asp148Glu | ||||||||||
| GG | 51 | 21 | 1.00 | 14 | 1.00 | NA | 46 | 1.00 | NA | |
| GT | 68 | 27 | 0.93 | 0.41-2.13 | 29 | 2.08 | 0.90-4.98 | 63 | 0.97 | 0.66-1.43 |
| TT | 53 | 22 | 1.13 | 0.46-2.79 | 17 | 0.90 | 0.34-2.33 | 50 | 0.96 | 0.64-1.45 |
| GT or TT | 121 | 49 | 1.00 | 0.48-2.14 | 46 | 1.49 | 0.70-3.30 | 113 | 0.96 | 0.68-1.37 |
| Total | 172 | 70 | NA | NA | 60 | NA | NA | 159 | NA | NA |
| XRCC1 Arg399Gln | ||||||||||
| GG* | 88 | 40 | 1.00 | 31 | 1.00 | NA | 81 | 1.00 | NA | |
| GA | 83 | 38 | 0.91 | 0.47-1.77 | 24 | 0.87 | 0.44-1.73 | 78 | 1.12 | 0.82-1.54 |
| AA | 16 | 4 | 0.27 | 0.05-0.99 | 5 | 0.85 | 0.24-2.75 | 15 | 1.54 | 0.86-2.74 |
| GA or AA | 99 | 42 | 0.76 | 0.40-1.44 | 29 | 0.87 | 0.45-1.67 | 93 | 1.17 | 0.86-1.59 |
| Total | 187 | 82 | NA | NA | 60 | NA | NA | 174 | NA | NA |
| XRCC3 Thr241Met | ||||||||||
| CC* | 89 | 35 | 1.00 | NA | 35 | 1.00 | NA | 85 | 1.00 | NA |
| CT | 74 | 30 | 0.84 | 0.41-1.70 | 22 | 0.68 | 0.33-1.36 | 66 | 0.90 | 0.65-1.25 |
| TT | 15 | 8 | 1.90 | 0.54-6.95 | 4 | 0.67 | 0.16-2.33 | 13 | 0.83 | 0.46-1.50 |
| CT or TT | 89 | 38 | 0.97 | 0.50-1.89 | 26 | 0.68 | 0.35-1.32 | 79 | 0.89 | 0.65-1.21 |
| Total | 178 | 73 | NA | NA | 61 | NA | NA | 164 | NA | NA |
| ERCC1 IVS5+34C>A | ||||||||||
| CC* | 143 | 60 | 1.00 | NA | 48 | 1.00 | NA | 131 | 1.00 | NA |
| CA | 45 | 22 | 1.57 | 0.75-3.35 | 12 | 0.59 | 0.26-1.30 | 43 | 1.08 | 0.75-1.56 |
| AA | 4 | 1 | 0.50 | 0.02-4.27 | 2 | 1.51 | 0.16-14.28 | 4 | 2.04 | 0.74-5.62 |
| CA or AA | 49 | 23 | 1.43 | 0.6-2.97 | 14 | 0.65 | 0.29-1.38 | 47 | 1.13 | 0.79-1.60 |
| Total | 192 | 83 | NA | NA | 62 | NA | NA | 178 | NA | NA |
| XPD Lys751Gln | ||||||||||
| AA | 86 | 31 | 1.00 | 37 | 1.00 | NA | 80 | 1.00 | NA | |
| AC | 84 | 43 | 1.97 | 0.91-4.37 | 21 | 0.43 | 0.18-0.96 | 77 | 0.95 | 0.66-1.36 |
| CC | 27 | 11 | 1.57 | 0.44-5.53 | 6 | 0.24 | 0.05-0.97 | 25 | 1.04 | 0.58-1.87 |
| AC or CC | 111 | 54 | 1.89 | 0.90-4.01 | 27 | 0.39 | 0.17-0.83 | 102 | 0.97 | 0.68-1.36 |
| Total | 197 | 85 | NA | NA | 64 | NA | NA | 182 | NA | NA |
| XPD Asp312Asn | ||||||||||
| GG | 95 | 42 | 1.00 | 39 | 1.00 | NA | 88 | 1.00 | NA | |
| GA | 79 | 34 | 1.50 | 0.70-3.26 | 19 | 0.44 | 0.19-1.00 | 73 | 1.00 | 0.70-1.44 |
| AA | 19 | 6 | 0.31 | 0.05-1.43 | 6 | 1.04 | 0.24-4.21 | 18 | 2.31 | 1.19-4.49 |
| GA or AA | 98 | 40 | 1.20 | 0.58-2.51 | 25 | 0.52 | 0.24-1.11 | 91 | 1.11 | 0.79-1.57 |
| Total | 193 | 82 | NA | NA | 64 | NA | NA | 179 | NA | NA |
Estimates of ORs and HRs are adjusted for the following covariates: age (continuous), AML onset (de novo versus secondary), cytogenetic group (favorable, intermediate, unfavorable, unknown), peripheral blast percentage (continuous, unknown for 7 patients who are excluded from multivariate analyses).
NA indicates not applicable.